Opinion
Video
Considering Safety of Gene Therapy for Retinal Diseases
Author(s):
Experts continue their discussion of gene therapy, highlighting safety concerns and the need for more trials and data.
Summary
Experts continue their discussion on the potential of gene therapy; in particular, they explore the exciting prospect of developing an ocular biofactory within a patient's eye to produce a VEGF inhibitor. Diana Do, MD expresses enthusiasm for gene therapy but raises a critical point about the long-term safety concerns of these specialized delivery systems. She emphasizes the inability to “turn off” gene therapy and highlights the need to understand the implications of chronic VEGF suppression within the eye over an extended period. David Eichenbaum, MD acknowledges the importance of addressing safety concerns associated with gene therapy, including inflammation and adverse events.
This summary was AI-generated and edited for clarity.
